We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+28.73%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$435M
AUM Growth
+$127M
Cap. Flow
+$84M
Cap. Flow %
19.31%
Top 10 Hldgs %
52.49%
Holding
50
New
21
Increased
8
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$21.4M
2
SLGL icon
Sol-Gel Technologies
SLGL
+$19.8M
3
DRUG
Bright Minds Biosciences
DRUG
+$17.7M
4
ANNX icon
Annexon
ANNX
+$14.1M
5
ZBIO
Zenas BioPharma
ZBIO
+$11.8M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$19.9M
2
RAPT
RAPT Therapeutics
RAPT
+$19.7M
3
SLNO
Soleno Therapeutics
SLNO
+$18.5M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$14.4M
5
FULC icon
Fulcrum Therapeutics
FULC
+$9.05M

Sector Composition

Rank Sector Weight
1 Healthcare 93.83%

No holdings matched the selected filter criteria.

1 2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Great Point Partners held 50 positions worth $435M, up 41% from $308M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners deployed $84M of net new capital in Q1 2026, opening 21 new positions and adding to 8 existing holdings. Its largest new stake was Alumis Inc: 856,061 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Context Therapeutics, an estimated $5.71M trimmed.

  • Great Point Partners's largest Q1 2026 buy was Alumis Inc: 856,061 shares worth $18.9M.
  • Great Point Partners added most to Nektar Therapeutics in Q1 2026, an estimated $6.02M increase.
  • Great Point Partners's biggest Q1 2026 reduction was Context Therapeutics, cutting an estimated $5.71M.
  • Great Point Partners fully exited Disc Medicine in Q1 2026, selling an estimated $19.9M.
  • Great Point Partners's ten largest holdings make up 52% of its $435M portfolio in Q1 2026.
  • Great Point Partners opened 21 new positions and closed 8 in Q1 2026.
  • Great Point Partners's portfolio value rose 41% quarter-over-quarter to $435M.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.